CENYX BIOTECH
Live / Registered — Registered (as of 26 Mar 2024)
What this means for you
Registered since 26 Mar 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79343374
- Registration number
- 7333739
- Mark type
- Stylized text
- Filed
- 29 Apr 2022
- Published for opposition
- 09 Jan 2024
- Registered
- 26 Mar 2024
- Attorney of record
- Leigh Ann Lindquist
Goods and services
- Class 005 — Pharmaceuticals: Diagnostic reagents for medical or veterinary purposes; diagnostic preparations for medical or veterinary purposes; veterinary preparations for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes for animal and poultry; radio-isotope markers for therapeutic or diagnostic use; in vitro diagnostic preparations for medical purposes; vaccines; contrast media for use in medical imaging equipment; contrast media for in vivo imaging; drug delivery agents in the form of compounds, wrapping wafers, edible wafers that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations for the prevention of inflammatory disorders; non-prescription medicines, namely, medicinal preparations in the nature of pills, tablets, capsules, caplets, liquid drops, sachets, oral liquids, suspensions, liquids, semi-solids, creams, syrups, ointments, lotions, gels, sprays, emulations, oils, pessaries, suppositories, granules and films for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes; radioactive pharmaceutical preparations for use in vivo diagnostics or therapeutic use; diagnostic agents for medical purposes; biological preparations for medical purposes, namely, biological preparations for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes for medical or veterinary purposes; pharmaceuticals for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the treatment of cardiovascular disease; drug delivery agents in the form of tablets or capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the treatment of inflammatory diseases; antibodies for medical purposes
- Class 042 — Scientific and technological services: Scientific research in the nature of conducting clinical trials for others in the field of cardiovascular disease; scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research and development; Scientific research in the nature of conducting clinical trials for others in the field of medicine; analysis, and evaluation of medical product development services of others to assure compliance with industry standards; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of pharmacy
Owner
- Cenyx Biotech Inc., KR
- Cenyx Biotech Inc., KR
- Cenyx Biotech Inc., KR
Prosecution history
- 17 Nov 2024 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 06 Oct 2024 — FINAL DISPOSITION NOTICE SENT TO IB
- 06 Oct 2024 — FINAL DISPOSITION PROCESSED
- 27 Jun 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 26 Mar 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 26 Mar 2024 — REGISTERED-PRINCIPAL REGISTER
- 09 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jan 2024 — PUBLISHED FOR OPPOSITION
- 08 Jan 2024 — NOTIFICATION PROCESSED BY IB
- 20 Dec 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 20 Dec 2023 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 20 Dec 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Dec 2023 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 29 Nov 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 29 Nov 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER